title: The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
abstract: Risperidone is a recently introduced neuroleptic distinguished by a decreased incidence of extrapyramidal side effects (EPS). The mechanism of its low EPS is unclear. Since it has been shown that EPS is related to the level of D2 receptor occupancy, we studied nine patients receiving 2-6 mg/day of risperidone using [11C]-raclopride PET scans in order to determine the in vivo D2 receptor binding characteristics of risperidone. The mean level of receptor occupancy was 66% at 2 mg; 73% at 4 mg; and 79% at 6 mg. Three patients, those with the highest receptor occupancies, exhibited mild EPS, though none required anitparkinsonian medications. Our results suggest that at doses of 4-6 mg the in vivo D2 receptor occupancy of risperidone is similar to that of typical neuroleptics and higher than that of clozapine. This would suggest that the EPS benefits of risperidone cannot be explained by a low D2 binding but may be related to its high 5-HT2 affinity. However, the emergence of EPS at higher levels of D2 receptor occupancy, in this study and in previous clinical trials, would suggest that risperidone's high 5-HT2 affinity provides only a relative protection from EPS. And once the D2 occupancy exceeds a certain threshold this 'relative' 5-HT2-mediated protection from EPS may be lost.
authors.affiliation: Schizophrenia Research Program, Clarke Institute of Psychiatry, University of Toronto, ON, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Kapur
authors.forename: G
authors.initials: G
authors.lastname: Remington
authors.forename: R B
authors.initials: RB
authors.lastname: Zipursky
authors.forename: A A
authors.initials: AA
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Houle
mesh_terms: D000328:Adult; D017109:Akathisia, Drug-Induced / Q000209:etiology; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism*; D008297:Male; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D018967:Risperidone; D012559:Schizophrenia / Q000188:drug therapy / Q000378:metabolism; D014055:Tomography, Emission-Computed
chemical_list: D007555:Isoxazoles; D010880:Piperidines; D017448:Receptors, Dopamine D2; D018967:Risperidone